Month: July 2025

Introduction and Objective: T2D presents significant challenges to health outcomes, necessitating effective strategies to optimize glycemic levels. This study examines the impact of tech empowered personalized lifestyle coaching, encompassing diet, fitness, and mental wellness, on improving glycemic control in T2D.Methods: This interim analysis was conducted on 34 participants (HbA1c >8%) compared the test group (n=18) […]

Introduction and Objective: Epidemiological and genetic studies have shown that disruption of circadian rhythms leads to accelerated and worsened symptoms of metabolic syndrome. Studies indicate that core clock factor, BMAL1, is required for insulin-dependent skeletal muscle glucose uptake in lean mice. However, the role of the clock in skeletal muscle metabolism during metabolic stress is […]

Introduction and Objective: The cardio-renoprotective properties of sodium-glucose cotransporter-2 (SGLT-2) inhibitors, angiotensin receptor blockers (ARBs), and angiotensin-converting enzyme (ACE) inhibitors are well-documented; however, their effectiveness in primary prevention among individuals with diabetes mellitus and hypertension, without preexisting cardiovascular (CV) or kidney disease, remains uncertain. This study evaluates the potential synergistic benefits of combining SGLT-2 inhibitors […]

Introduction and Objective: Adipose tissue (AT) is a central regulator of energy homeostasis and systemic metabolism. Dysfunctional AT expansion during obesity is a major driver of metabolic diseases, particularly type 2 diabetes. Mesenchymal progenitor cells (MPCs), a heterogeneous and dynamic cell population, play a critical yet poorly understood role in AT expansion and function. In […]

Introduction and Objective: The American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) recommend glucagon-like peptide-1 receptor agonists (GLP1-RA) for type 2 diabetes, but their use in type 1 diabetes (T1D) is limited. This study compared glycemic metrics and adverse events in fasting and non-fasting people with T1D using GLP1-RA during […]

Introduction and Objective: ALK7 plays a crucial role in adipose homeostasis, with genetic variants linked to obesity in human GWAS. This study examines the pharmacodynamic effects of SGB-ALK7 in cynomolgus monkeys and its therapeutic potential in an obese mouse model.Methods: SanegeneBio is developing Ligand and Enhancer Assisted Delivery (LEAD™) technology, which utilizes a receptor-mediated internalization […]

Introduction and Objective: The prevalence of type 1 diabetes (T1D) in older adults has increased over the last few decades. Many aspects of self-care may be impacted by age related changes, comorbidities, and risk of hypoglycemia. Yet, few studies have characterized the emotional burden of diabetes distress (DD) in this age group and its clinical […]

Introduction and Objective: Continuous blood glucose monitoring in mice using implantable telemetry devices is a highly sophisticated technique that measures real-time arterial blood glucose. This technique has not yet been combined with indirect calorimetry to study metabolism in obesity. By combining these techniques, this study was designed to gain a higher resolution understanding of the […]

Introduction and Objective: HRS9531, a novel once-weekly (QW) dual GLP-1/GIP receptor agonist, showed preliminary efficacy with good tolerability in T2DM participants. This phase 2 study further evaluated the efficacy and safety of HRS9531 in Chinese T2DM participants with treatment to 32 weeks which consisted of a 20-week (W) core treatment followed by a 12W extension […]

Introduction and Objective: In a large animal model of type 2 diabetes (T2D), we have shown that portal, GLP-1-dependent, glucose sensing is impaired and a low-dose dihydrotestosterone (DHT) implant inserted into the area of the portal sensor normalizes glucose metabolism acutely. We evaluated the capacity of portal DHT to achieve sustained remission of diabetes and […]